Our Drug Delivery Systems

BeloGal

The BeloGal® technology was developed by Double Bond Pharmaceutical and the patent application is in process (PCT /EP2017/025035). A Freedom to Operate search in the U.S. and EU did not reveal any comparable drug delivery technologies. BeloGal is based on biomimetic encapsulation of the active pharmaceutical ingredient (API) with a polymer- and biology-free excipient that radically increases the therapeutic effect of the API at the target site while protecting the remaining healthy tissues from toxic effects. Preliminary results show a 10-fold dose in lungs and 3-4-fold in liver compared to other organs. The technology is currently in development for lung and liver cancer therapies.

Hydrogels

Temodex/SI-053 utilizes hydrogel to allow the delivery of active pharmaceutical ingredient (API) to the resection cavity. Hydrogels are 3D macromolecular polymeric chains that can be easily molded into any form, shape, and size. They do not dissolve and can absorb thousands of times of their own dry weight in water. These groups assist in absorbing the large fraction of biological fluid or water and thus help in the formation of the hydrogel. Hydrogels also have a porous structure, which can be modulated by controlling the density of the cross-links in the gel matrix. Their porosity allows the incorporation of the API into the gel matrix and delivery of the API through the polymeric gel network in a controlled manner over a long period of time.